Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of atopic dermatitis (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AD for each…

Clarivate Epidemiology’s coverage of atopic dermatitis/atopic eczema (AD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

The human immunodeficiency virus (HIV) therapy market is dynamic and growing. With the launches of many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy and ViiV’s Dovato,…

The treatment journey for multiple sclerosis (MS) patients in the United States continues to evolve; nearly 20 immunomodulatory disease-modifying therapies (DMTs) are now available to treat the…

Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of AD…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Atopic Dermatitis patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of atopic dermatitis (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AD for each…

Clarivate Epidemiology’s coverage of alzheimer’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of alzheimer’s…

Clarivate Epidemiology’s coverage of atopic dermatitis (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AD for each…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AD patient populations, covering 171 countries and more than 99% of…

The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…

The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the treatment of this disease. In 2021, Keytruda (Merck & Co.) became the first…